BRIACELL THERAPEUTICS CORP (BCTX) Stock Fundamental Analysis

NASDAQ:BCTX • CA1079303071

3.67 USD
-0.09 (-2.39%)
At close: Feb 24, 2026
3.79 USD
+0.12 (+3.27%)
After Hours: 2/24/2026, 7:37:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, BCTX scores 2 out of 10 in our fundamental rating. BCTX was compared to 521 industry peers in the Biotechnology industry. While BCTX seems to be doing ok healthwise, there are quite some concerns on its profitability. BCTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BCTX had negative earnings in the past year.
  • BCTX had a negative operating cash flow in the past year.
  • In the past 5 years BCTX always reported negative net income.
  • In the past 5 years BCTX always reported negative operating cash flow.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of BCTX (-219.56%) is worse than 89.44% of its industry peers.
  • BCTX's Return On Equity of -287.71% is on the low side compared to the rest of the industry. BCTX is outperformed by 72.94% of its industry peers.
Industry RankSector Rank
ROA -219.56%
ROE -287.71%
ROIC N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K 1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • BCTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BCTX has been increased compared to 5 years ago.
  • There is no outstanding debt for BCTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -11.46, we must say that BCTX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.46, BCTX is not doing good in the industry: 75.05% of the companies in the same industry are doing better.
  • There is no outstanding debt for BCTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.46
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

  • BCTX has a Current Ratio of 3.42. This indicates that BCTX is financially healthy and has no problem in meeting its short term obligations.
  • BCTX has a Current ratio of 3.42. This is comparable to the rest of the industry: BCTX outperforms 41.27% of its industry peers.
  • BCTX has a Quick Ratio of 3.42. This indicates that BCTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.42, BCTX is in line with its industry, outperforming 43.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for BCTX have decreased strongly by -184.87% in the last year.
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BCTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.83% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BCTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BCTX's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BCTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (2/24/2026, 7:37:18 PM)

After market: 3.79 +0.12 (+3.27%)

3.67

-0.09 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15
Earnings (Next)03-10
Inst Owners4.75%
Inst Owner Change-22.71%
Ins Owners0.2%
Ins Owner Change0%
Market Cap26.61M
Revenue(TTM)N/A
Net Income(TTM)-28.71M
Analysts80
Price TargetN/A
Short Float %1.97%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.67
P/tB 2.72
EV/EBITDA N/A
EPS(TTM)-128.19
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-3.99
FCFYN/A
OCF(TTM)-3.99
OCFYN/A
SpS0
BVpS1.38
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -219.56%
ROE -287.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -11.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.98%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCTX FAQ

What is the ChartMill fundamental rating of BRIACELL THERAPEUTICS CORP (BCTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BCTX.


Can you provide the valuation status for BRIACELL THERAPEUTICS CORP?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCTX). This can be considered as Overvalued.


What is the profitability of BCTX stock?

BRIACELL THERAPEUTICS CORP (BCTX) has a profitability rating of 0 / 10.


How financially healthy is BRIACELL THERAPEUTICS CORP?

The financial health rating of BRIACELL THERAPEUTICS CORP (BCTX) is 6 / 10.